In its review, CHMP concluded that dronedarone increases the risk of injury to the liver and the lungs and may increase the risk of cardiovascular side effects in some patients with non-permanent AF.
The review was broadened in July when the PALLAS trial of dronedarone for the treatment of permanentAF was terminated early due to a significant increase in cardiovascular events in the dronedarone arm of the trial.